Study Phase 1

A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Paliperidone Palmitate 3-Month Formulation in Subjects With Schizophrenia

Trial Information

Generic NamePaliperidone palmitateProduct NameINVEGA SUSTENNA®Therapeutic AreaNervous SystemProduct ClassPsycholepticsPharmacological SubgroupAntipsychoticsChemical SubgroupOther AntipsychoticsCondition StudiedSchizophrenia
Sponsor Protocol NumberR092670PSY1005Enrollment328Data PartnerJohnson & Johnson% Female33.5%Mean/Median Age (Years)41.9% White56.6%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.